Crack cocaine addiction
Conditions
Interventions
Case Group: 20 female crack cocaine users will perform an experimental session with functional magnetic resonance imaging with cognitive tasks, followed by another experimental session with functional
or a dose of intranasal spray with placebo solution (only the vehicle used for intranasal oxytocin spray). The definition of which session (first or second) will inhale oxytocin or placebo will be ran
or a dose of intranasal spray with placebo solution (only the vehicle used for
Drug
Behavioural
HP3.073.433.101
N06.850.460.350.112
Sponsors
Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq
Departamento de Ciência e Tecnologia da Secretaria de Ciência, Tecnologia e Insumos Estratégicos
Secretaria Nacional de Políticas Sobre Drogas
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: For both groups: female; age 18-50 years; absence of menopause; with right-handed manual dominance; HIV-; no metals in the body; no recent tattoo (2 months), BHCG -; declare abstainers from non-tobacco drugs in the last 2 weeks; no evidence of claustrophobia, no history of eye, ear and brain surgery; no administration of benzodiazepines and neuroleptics in the last 24 hours; no history of head trauma, literate. For the control group: Declare no substance-related disorder. For the case group: Diagnosis of cocaine-related disorder (crack) according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition.
Exclusion criteria
Exclusion criteria: Controls reporting on use of psychiatric medications; positive urine test for cocaine, benzodiazepine, amphentamine, opioids and alcohol; illiterate; Psychotic syndromes; have been pregnant for the past 6 months; have an IQ <70; neurological disease; metal prostheses; and / or tattoos or other metallic artifacts that make magnetic resonance imaging unfeasible. Possess claustrophobia; chronic respiratory disease; deviated septum type III; presence of lesions in the nasal mucosa; history of head injury; or currently have nasal congestion. Healthy group participants with ongoing mental disorders; crack users who have declared themselves abstinent for more than two months.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Lower subjective craving for crack while watching crack cues measured by a visual analogic scale considering 5% of variation in the means under intranasal oxytocin use in comparison to placebo solution use. | — |
Primary
| Measure | Time frame |
|---|---|
| Increased prefrontal interhemispheric brain functional connectivity during resting-state measured by Voxel-Mirrored Homotopic Connectivity for interpretation of data from functional magnetic ressonance imaging exam considering 5% of variations between the means for intranasal oxytocin use and intranasal placebo solution use. | — |
Countries
Brazil
Contacts
Public ContactRodrigo de Oliveira
Pontifícia Universidade Católica do Rio Grande do Sul
Outcome results
None listed